Skip to main content
Medicines, medical devices

Guidance and regulation

Skip to results
406 results sorted by Most viewed
  • How to apply for a clinical trial from 28 April 2026, including eligibility, documentation and registration in a public registry.

  • Information about the MHRA graduate scheme which is currently closed for applications.

  • Patient factsheet to provide information on vaccines and vaccine safety.

  • Fees payable to the MHRA from 2025.

  • How to interpret post-market surveillance (PMS) requirements for medical devices in Great Britain.

  • Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.

  • Guidance for UK wholesalers and manufacturers on how to import human medicines including unlicensed medicines, how to apply for a licence and how much it costs.

  • Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.

  • A wholesale dealer in Great Britain may import Qualified Person certified medicines from the European Economic Area if certain checks are made by the ‘Responsible Person (import)’

  • Guidance on using non-investigational medicinal products in a clinical trial.

  • How to register on the MHRA portal and use it to apply for and update marketing authorisations and make other applications.

  • Details of the organisations that are currently approved to undertake conformity assessments on medical devices.

  • Guidance on transitional arrangements for the Clinical Trials Regulations

  • You must include the appropriate legal basis for your application when you apply to MHRA for a marketing authorisation.

  • How to apply for a traditional herbal registration (THR) to market a herbal medicine in the UK.

  • Anyone in Northern Ireland selling medicines to the public via a website must still comply with the requirement to apply the EU common logo.

  • You must get permission to export certain drugs and medicines.

  • How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.

  • These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.

  • How the MHRA makes decisions on whether a borderline product is a medical device and which risk class should apply.